Why the Paradigm (ASX:PAR) share price is pushing higher today

There's positive news from a study to treat osteoarthritis…

| More on:
a smiling elderly couple, the man uses a walking stick, are walking a dog on a lead.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is up 1.85% at time of writing to $1.93 per share. That's a lift of more than 5% from its low of $1.83 in early morning trade.

Below, we take a look at what's helping drive today's rebound for the ASX healthcare share.

What did Paradigm report to the market?

The Paradigm share price is gaining after the company released a positive update on its Phase 2 Synovial Fluid Biomarker study.

The study involves participants with knee osteoarthritis (OA) and is "investigating changes in synovial fluid biomarkers associated with pain, inflammation and disease progression of OA".

Paradigm said it has received approval from the ethics committee for its amendment to the Phase 2 study to evaluate the effectiveness of pentosan polysulfate sodium (PPS) (Zilosul) compared with a placebo.

The now approved amendments will see a once aweek dosing regimen along with a follow-up period of 12 months, up from the previous 6-month follow-up. A new site will also operate in New South Wales to increase patient recruitment which the company said has been hampered by COVID lockdowns in Victoria.

In addition, Paradigm also received approval from the ethics committee to conduct a parallel clinical trial in dogs. The company said the pathophysiology of OA is similar in humans and dogs. It expects to gain "relevant translational data" from the canine study.

Commenting on the trial progression, Paradigm's chief medical officer Donna Skerrett said:

Paradigm is embarking on a number of approaches to further value PPS in the knee OA indication by exploring synovial biomarkers and evaluating duration of effect in clinical studies. Simultaneously, we are enhancing our understanding of mechanism of action and disease modifying potential by evaluating PPS in a canine OA study.

The combined information of these two studies will allow us to assess the potential disease modification capability of our OA program while we initiate the phase 2/3 pivotal study activity to assess PPS safety and efficacy for the pain and function indication.

Paradigm share price snapshot

The Paradigm share price has struggled this calendar year, down 24%. By comparison the All Ordinaries Index (ASX: XAO) has gained 12% year-to-date.

Over the past month, Paradigm shares are down 4%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »